HLA-B27 PCR Assay

Details for Product No. ABIN2648748, Supplier: Log in to see
Application
Polymerase Chain Reaction (PCR)
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Purpose MutaGEL® HLA B-27 kit allows for the analysis of DNA in respect to the detection of the HLA-B27 alleles present in a human probe.
Brand MutaGEL®
Sample Type DNA
Characteristics Patients with Ancylosing Spondylitis (Morbus Bechterew = M. B.) have cell surface molecules of the HLA-B27 group in 90 % of the cases, whereas the normal abundancy is only up to 10 % positives. Absence of HLA-B27 alleles in a person can therefore diminish the probability of a M. B. diagnosis in the internistically demanding diagnosis of spondylarthropathies (especially in young people). Additionally segregation between certain "disease coupled" B27- types has been worked out by the modern molecular medical research (actually there are now 45 human HLA-B27 alleles known differing in amino acid changes in their protein sequence – an “update” for MutaGEL® HLA B27 is done periodically). Of epidemiological relevance are only the alleles *2701 - *2710; all other HLAB27 types are described in single cases only.

That means, only some of the HLA-B27 allele types are abundant: Types *2701, -02, -04, -05, -07, -08 and -10 are associated with the chronic inflammatory rheumatic disease M. B. and population studies for them are available. The types *2706, -09, -12 and -18 are not associated with M. B., most of the others having been reported only once. This variability characterizes the frame of the diagnostic demand, keeping in mind the possibility of occurrence of further new sequence findings.
Comment

MutaGEL® HLA-B27 PCR Assay Kit contains reagents for two types of DNA amplification: Test A is a “surveying” approach, which can detect all known sequences of the HLA-B27 group contained in a human probe (= types *2701 - *2745). On the other hand Test B gives positive results with nearly all known M. B. associated B27- types, especially again alleles *2705 and *2702, who together asymptotically add to 100 % in Middle European -B27 carriers and M. B. patients. Test B additionally sees allele *2704 from M. B. cases of Asia, whereas the presumably protectives *2706 and famous *2709 are excluded from its amplification.

Therefore Test A should be done for the general HLA-B27 search and Test B for the analysis of existence of alleles associated with HLA-B27 disease (of course the alleles seen by Test B are all detected by Test A also and direct comparison allows for conclusion on protective alleles).

Sample Volume 200 μL
Restrictions For Research Use only
Storage -20 °C